Literature DB >> 19027279

Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.

Anna Amadori1, Andrea Antonelli, Ilaria Balteri, Anja Schreiber, Massimiliano Bugiani, Virginia De Rose.   

Abstract

Obstructive lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF). To identify risk factors contributing to FEV(1) decline in CF patients, we carried out a retrospective analysis of clinical and pulmonary function data in a population of CF patients followed up for 5 years and studied the correlation between clinical data and FEV(1) decline. Fifty-one adult CF patients were studied. The FEV(1) decline was related to the following clinical characteristics: CFTR genotype, age, gender, weight, height, age at diagnosis, baseline FEV(1), pancreatic function, presence of airway infection, pancreatic insufficiency and diabetes, number of exacerbations/year and intravenous (i.v.) antibiotic courses/year. Both the number of exacerbations/year and the number of i.v. antibiotic courses/year were strongly related to the FEV(1) decline. Patients with airway infection or with diabetes had significantly lower FEV(1) values during the study as compared with non-infected patients or patients without diabetes; however, both the presence of airway infection or diabetes did not affect the FEV(1) decline. These results suggest that the aggressive treatment of disease exacerbations is crucial for delaying lung function decline in CF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027279     DOI: 10.1016/j.rmed.2008.09.024

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  22 in total

1.  Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.

Authors:  Joshua R Stokell; Raad Z Gharaibeh; Timothy J Hamp; Malcolm J Zapata; Anthony A Fodor; Todd R Steck
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 3.  Exposure Memory and Lung Regeneration.

Authors:  Young-Mi Go; Dean P Jones
Journal:  Ann Am Thorac Soc       Date:  2016-12

Review 4.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

5.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Authors:  Peter G Middleton; Marcus A Mall; Pavel Dřevínek; Larry C Lands; Edward F McKone; Deepika Polineni; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; François Vermeulen; Gautham Marigowda; Charlotte M McKee; Samuel M Moskowitz; Nitin Nair; Jessica Savage; Christopher Simard; Simon Tian; David Waltz; Fengjuan Xuan; Steven M Rowe; Raksha Jain
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245

6.  Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

Authors:  Donald R VanDevanter; David J Pasta; Michael W Konstan
Journal:  J Cyst Fibros       Date:  2015-03-06       Impact factor: 5.482

7.  Risk factors for totally implantable venous access device-associated complications in cystic fibrosis.

Authors:  C McCarthy; O O'Carroll; M E O'Brien; T McEnery; A Franciosi; C Gunaratnam; N G McElvaney
Journal:  Ir J Med Sci       Date:  2017-08-15       Impact factor: 1.568

8.  Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.

Authors:  Eric Raphael Gottlieb; Elisabeth Christine Smith; Linda Lucetta Wolfenden; Richard Mark Allman; Vin Tangpricha
Journal:  Clin Respir J       Date:  2010-10-01       Impact factor: 2.570

9.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

10.  Microbial Interactions in the Cystic Fibrosis Airway.

Authors:  Ann M Granchelli; Frederick R Adler; Ruth H Keogh; Christiana Kartsonaki; David R Cox; Theodore G Liou
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.